[Form 3] Iovance Biotherapeutics, Inc. Initial Statement of Beneficial Ownership
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Rosinack Matthew W.
Role
SVP, Finance (Int. PFO & PAO)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 75,000 contracts (Direct);
Restricted Stock Units — 109,068 contracts (Direct);
Common Stock — 89,129 shares (Direct)
Footnotes (6)
- F1. Includes 9,089 shares of Iovance Biotherapeutics, Inc.'s (the "Issuer") common stock purchased under the Issuer's 2020 Employee Stock Purchase Plan.
- F2. The stock option was granted on September 27, 2021. The shares underlying this option are fully vested.
- F3. The restricted stock units ("RSUs") were granted on March 2, 2023. One-third of the RSUs vested on March 2, 2024. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter.
- F4. The RSUs were granted on March 1, 2024. One-third of the RSUs vested on March 1, 2025. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter.
- F5. The RSUs were granted on March 5, 2025. One-third of the RSUs will vest on March 5, 2026. The remaining RSUs will vest in eight equal quarterly installments thereafter.
- F6. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
